Immunomedics of Morris Plains, NJ, has submitted a biologies licenseapplication to the Food and Drug Administration for approval ofLeukoScan, a technetium-99m-labeled monoclonal antibody-basedagent for imaging bone infection. LeukoScan received a
Immunomedics of Morris Plains, NJ, has submitted a biologies license
application to the Food and Drug Administration for approval of
LeukoScan, a technetium-99m-labeled monoclonal antibody-based
agent for imaging bone infection. LeukoScan received a positive
recommendation from Europe's Committee for Proprietary Medicinal
Products in October (SCAN 10/23/96).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.